Kiniksa Pharmaceuticals International (KNSA) Profit After Tax (2017 - 2026)

Kiniksa Pharmaceuticals International's Profit After Tax history runs 10 years deep, the most recent figure standing at $22.6 million for Q1 2026.

• Quarterly Profit After Tax rose 1129700.0% year-over-year to $22.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.0 million (up 536.21% YoY) and the FY2025 annual result came in at $59.0 million, up 35014.2% from the prior year.
• Profit After Tax was $22.6 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $14.2 million in the prior quarter.
• Across five years, Profit After Tax topped out at $224.1 million in Q3 2022 and bottomed at -$25.2 million in Q1 2022.
• A 5-year average of $13.2 million and a median of -$2000.0 in 2025 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax sank 126.1% — and 2026, when it soared 1129700.0%.
• Kiniksa Pharmaceuticals International's Profit After Tax stood at $4.6 million in 2022, then soared by 208.27% to $14.1 million in 2023, then sank by 100.87% to -$122000.0 in 2024, then jumped by 11738.52% to $14.2 million in 2025, then jumped by 59.11% to $22.6 million in 2026.
• Business Quant data shows KNSA's Profit After Tax at $22.6 million in Q1 2026, $14.2 million in Q4 2025, and $18.3 million in Q3 2025.